 Matthew Rossman
Concepts (260)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vasodilation | 20 | 2025 | 476 | 2.870 |
Why?
| | Endothelium, Vascular | 17 | 2025 | 902 | 2.760 |
Why?
| | Exercise | 23 | 2023 | 1934 | 2.570 |
Why?
| | Aging | 19 | 2024 | 1774 | 2.500 |
Why?
| | Antioxidants | 6 | 2023 | 558 | 2.150 |
Why?
| | Leg | 15 | 2022 | 240 | 2.040 |
Why?
| | Mitochondria | 6 | 2025 | 875 | 1.670 |
Why?
| | Brachial Artery | 8 | 2025 | 192 | 1.640 |
Why?
| | Nitric Oxide | 14 | 2023 | 896 | 1.640 |
Why?
| | Oxidative Stress | 13 | 2025 | 1264 | 1.640 |
Why?
| | Vascular Stiffness | 9 | 2024 | 467 | 1.450 |
Why?
| | Vascular Diseases | 5 | 2023 | 240 | 1.280 |
Why?
| | Muscle Fatigue | 5 | 2017 | 101 | 1.280 |
Why?
| | Blood Vessels | 3 | 2020 | 187 | 1.170 |
Why?
| | Pulmonary Ventilation | 2 | 2022 | 78 | 1.160 |
Why?
| | Reactive Oxygen Species | 11 | 2025 | 592 | 1.010 |
Why?
| | Femoral Artery | 9 | 2016 | 174 | 1.000 |
Why?
| | Ascorbic Acid | 3 | 2021 | 120 | 0.970 |
Why?
| | Endothelial Cells | 8 | 2025 | 749 | 0.970 |
Why?
| | Regional Blood Flow | 14 | 2022 | 463 | 0.940 |
Why?
| | Muscle, Skeletal | 15 | 2024 | 1644 | 0.940 |
Why?
| | Movement | 8 | 2022 | 270 | 0.920 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 5 | 2017 | 1000 | 0.900 |
Why?
| | NAD | 1 | 2023 | 74 | 0.820 |
Why?
| | Postmenopause | 1 | 2025 | 349 | 0.800 |
Why?
| | Citrulline | 1 | 2022 | 43 | 0.750 |
Why?
| | Quadriceps Muscle | 7 | 2021 | 129 | 0.740 |
Why?
| | Cellular Senescence | 3 | 2023 | 173 | 0.740 |
Why?
| | Healthy Lifestyle | 2 | 2018 | 32 | 0.730 |
Why?
| | Sodium Nitrite | 1 | 2021 | 39 | 0.700 |
Why?
| | Bronchi | 1 | 2022 | 249 | 0.680 |
Why?
| | Aged | 32 | 2024 | 22107 | 0.650 |
Why?
| | Stroke Volume | 4 | 2019 | 593 | 0.620 |
Why?
| | Cardiovascular Diseases | 6 | 2024 | 2008 | 0.600 |
Why?
| | Exercise Tolerance | 5 | 2023 | 273 | 0.580 |
Why?
| | Anti-Asthmatic Agents | 1 | 2022 | 374 | 0.570 |
Why?
| | Mitochondria, Muscle | 5 | 2021 | 111 | 0.560 |
Why?
| | Dietary Supplements | 5 | 2023 | 532 | 0.560 |
Why?
| | Heating | 1 | 2017 | 20 | 0.550 |
Why?
| | Muscle Contraction | 7 | 2021 | 423 | 0.500 |
Why?
| | Humans | 62 | 2025 | 129847 | 0.480 |
Why?
| | Asthma | 2 | 2022 | 2225 | 0.470 |
Why?
| | Fatigue | 2 | 2014 | 319 | 0.470 |
Why?
| | Young Adult | 22 | 2024 | 12467 | 0.450 |
Why?
| | Arteries | 5 | 2024 | 266 | 0.450 |
Why?
| | Hyperemia | 5 | 2022 | 48 | 0.450 |
Why?
| | Physical Endurance | 2 | 2013 | 264 | 0.450 |
Why?
| | Heart | 1 | 2018 | 645 | 0.440 |
Why?
| | Vasoconstriction | 6 | 2022 | 199 | 0.440 |
Why?
| | Thioctic Acid | 1 | 2013 | 10 | 0.420 |
Why?
| | Male | 42 | 2024 | 63759 | 0.410 |
Why?
| | Vitamin E | 1 | 2013 | 120 | 0.410 |
Why?
| | Nitrates | 3 | 2022 | 88 | 0.400 |
Why?
| | Middle Aged | 20 | 2025 | 31177 | 0.400 |
Why?
| | Smoking Water Pipes | 2 | 2023 | 8 | 0.400 |
Why?
| | Water Pipe Smoking | 2 | 2023 | 9 | 0.400 |
Why?
| | Knee | 1 | 2012 | 63 | 0.380 |
Why?
| | Female | 29 | 2025 | 68829 | 0.370 |
Why?
| | Blood Flow Velocity | 6 | 2019 | 406 | 0.350 |
Why?
| | Resistance Training | 2 | 2023 | 151 | 0.350 |
Why?
| | Cross-Over Studies | 3 | 2023 | 521 | 0.350 |
Why?
| | Diet, Western | 2 | 2021 | 79 | 0.350 |
Why?
| | Adult | 23 | 2025 | 35634 | 0.340 |
Why?
| | Healthy Volunteers | 4 | 2021 | 201 | 0.340 |
Why?
| | Oxygen Consumption | 7 | 2018 | 672 | 0.330 |
Why?
| | Exercise Test | 3 | 2022 | 614 | 0.320 |
Why?
| | Blood Pressure | 7 | 2023 | 1736 | 0.310 |
Why?
| | Posture | 5 | 2016 | 175 | 0.300 |
Why?
| | Electromyography | 4 | 2014 | 381 | 0.300 |
Why?
| | Caloric Restriction | 2 | 2020 | 111 | 0.290 |
Why?
| | Atherosclerosis | 3 | 2018 | 402 | 0.280 |
Why?
| | Inflammation | 6 | 2024 | 2748 | 0.270 |
Why?
| | Hand Strength | 3 | 2023 | 113 | 0.270 |
Why?
| | Physical Conditioning, Animal | 2 | 2021 | 236 | 0.260 |
Why?
| | Respiratory Function Tests | 2 | 2022 | 581 | 0.250 |
Why?
| | Motor Activity | 4 | 2024 | 684 | 0.250 |
Why?
| | Feedback, Physiological | 3 | 2014 | 76 | 0.240 |
Why?
| | Sympathetic Nervous System | 3 | 2023 | 174 | 0.240 |
Why?
| | Respiratory Muscles | 2 | 2023 | 32 | 0.240 |
Why?
| | Premenopause | 1 | 2025 | 120 | 0.230 |
Why?
| | Age Factors | 5 | 2024 | 3161 | 0.220 |
Why?
| | Pulse Wave Analysis | 5 | 2023 | 248 | 0.220 |
Why?
| | Spermidine | 1 | 2024 | 18 | 0.220 |
Why?
| | Flavonols | 1 | 2023 | 12 | 0.220 |
Why?
| | Animals | 14 | 2024 | 35409 | 0.220 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 2024 | 110 | 0.220 |
Why?
| | Arterial Pressure | 5 | 2019 | 119 | 0.210 |
Why?
| | Nicotinamide Mononucleotide | 1 | 2023 | 9 | 0.210 |
Why?
| | Lipoproteins, LDL | 1 | 2023 | 127 | 0.200 |
Why?
| | Endothelin-1 | 2 | 2016 | 180 | 0.200 |
Why?
| | Acetylcholine | 2 | 2023 | 184 | 0.200 |
Why?
| | Vaping | 1 | 2023 | 55 | 0.200 |
Why?
| | Adolescent | 7 | 2023 | 20451 | 0.200 |
Why?
| | Mice, Inbred C57BL | 5 | 2024 | 5468 | 0.190 |
Why?
| | Electronic Nicotine Delivery Systems | 1 | 2023 | 90 | 0.190 |
Why?
| | Social Class | 1 | 2024 | 259 | 0.190 |
Why?
| | Administration, Oral | 2 | 2015 | 787 | 0.190 |
Why?
| | Treatment Outcome | 4 | 2022 | 10241 | 0.190 |
Why?
| | Mice | 10 | 2024 | 16983 | 0.180 |
Why?
| | Spirostans | 1 | 2021 | 4 | 0.180 |
Why?
| | Breathing Exercises | 1 | 2021 | 20 | 0.180 |
Why?
| | Inhalation | 1 | 2021 | 28 | 0.180 |
Why?
| | Hypertension | 2 | 2021 | 1242 | 0.180 |
Why?
| | Cardiovascular System | 3 | 2020 | 136 | 0.180 |
Why?
| | Double-Blind Method | 3 | 2023 | 1877 | 0.180 |
Why?
| | Hypotension | 1 | 2022 | 117 | 0.180 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2021 | 102 | 0.170 |
Why?
| | Dementia | 1 | 2023 | 227 | 0.170 |
Why?
| | Cells, Cultured | 2 | 2025 | 4102 | 0.160 |
Why?
| | Cardiovascular Abnormalities | 1 | 2019 | 13 | 0.160 |
Why?
| | Pressoreceptors | 1 | 2019 | 19 | 0.160 |
Why?
| | Glucose Intolerance | 1 | 2021 | 142 | 0.160 |
Why?
| | Drug Monitoring | 1 | 2021 | 216 | 0.160 |
Why?
| | Supine Position | 2 | 2016 | 38 | 0.160 |
Why?
| | Models, Animal | 1 | 2021 | 376 | 0.160 |
Why?
| | DNA Methylation | 1 | 2024 | 606 | 0.150 |
Why?
| | Receptors, Adrenergic, beta-1 | 1 | 2019 | 46 | 0.150 |
Why?
| | Coronary Circulation | 1 | 2019 | 139 | 0.150 |
Why?
| | Electron Transport | 1 | 2018 | 112 | 0.150 |
Why?
| | Hemodynamics | 6 | 2023 | 1094 | 0.150 |
Why?
| | Athletes | 1 | 2022 | 411 | 0.150 |
Why?
| | Biomarkers | 3 | 2021 | 3971 | 0.150 |
Why?
| | Peptides, Cyclic | 3 | 2016 | 256 | 0.150 |
Why?
| | Fasting | 1 | 2020 | 268 | 0.150 |
Why?
| | Energy Metabolism | 2 | 2021 | 875 | 0.150 |
Why?
| | Aorta | 4 | 2024 | 408 | 0.140 |
Why?
| | Oncogene Protein p21(ras) | 1 | 2017 | 16 | 0.140 |
Why?
| | Endothelin Receptor Antagonists | 2 | 2016 | 62 | 0.140 |
Why?
| | Habits | 1 | 2017 | 44 | 0.140 |
Why?
| | Heart Rate | 6 | 2023 | 804 | 0.140 |
Why?
| | Coronary Vessels | 1 | 2019 | 239 | 0.140 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2018 | 203 | 0.140 |
Why?
| | Bicycling | 2 | 2021 | 116 | 0.130 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2023 | 567 | 0.130 |
Why?
| | Congresses as Topic | 1 | 2018 | 216 | 0.130 |
Why?
| | Primary Prevention | 1 | 2018 | 190 | 0.130 |
Why?
| | Cardiac Catheterization | 1 | 2019 | 520 | 0.120 |
Why?
| | Metabolomics | 1 | 2021 | 652 | 0.120 |
Why?
| | Reproducibility of Results | 3 | 2022 | 3089 | 0.120 |
Why?
| | Cardiovascular Physiological Phenomena | 1 | 2015 | 42 | 0.120 |
Why?
| | Ventricular Function, Left | 1 | 2019 | 529 | 0.120 |
Why?
| | Reflex | 1 | 2015 | 65 | 0.120 |
Why?
| | Autonomic Nervous System | 1 | 2015 | 75 | 0.120 |
Why?
| | Life Style | 1 | 2017 | 462 | 0.120 |
Why?
| | Cell Respiration | 3 | 2021 | 98 | 0.110 |
Why?
| | Maximal Midexpiratory Flow Rate | 1 | 2014 | 3 | 0.110 |
Why?
| | Peak Expiratory Flow Rate | 1 | 2014 | 36 | 0.110 |
Why?
| | Muscle Strength | 3 | 2023 | 304 | 0.110 |
Why?
| | Pyramidal Tracts | 1 | 2014 | 26 | 0.110 |
Why?
| | omega-N-Methylarginine | 4 | 2015 | 26 | 0.110 |
Why?
| | Bronchoconstriction | 1 | 2014 | 31 | 0.110 |
Why?
| | Ultrasonography, Doppler | 4 | 2016 | 118 | 0.110 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 1 | 2014 | 36 | 0.110 |
Why?
| | Receptors, Opioid, mu | 1 | 2014 | 66 | 0.110 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2017 | 385 | 0.110 |
Why?
| | Shear Strength | 1 | 2014 | 67 | 0.110 |
Why?
| | Extremities | 1 | 2014 | 127 | 0.110 |
Why?
| | Cardiac Output | 4 | 2015 | 157 | 0.110 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2017 | 503 | 0.110 |
Why?
| | Vital Capacity | 1 | 2014 | 290 | 0.100 |
Why?
| | Electron Spin Resonance Spectroscopy | 1 | 2013 | 91 | 0.100 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2016 | 444 | 0.100 |
Why?
| | Free Radicals | 1 | 2013 | 106 | 0.100 |
Why?
| | Recovery of Function | 1 | 2017 | 645 | 0.100 |
Why?
| | Forced Expiratory Volume | 1 | 2014 | 508 | 0.100 |
Why?
| | Coronary Artery Disease | 1 | 2019 | 680 | 0.100 |
Why?
| | Fentanyl | 3 | 2021 | 81 | 0.100 |
Why?
| | Single-Blind Method | 1 | 2013 | 271 | 0.100 |
Why?
| | Bronchodilator Agents | 1 | 2014 | 245 | 0.100 |
Why?
| | Drug Combinations | 1 | 2013 | 331 | 0.100 |
Why?
| | Central Nervous System | 1 | 2014 | 256 | 0.090 |
Why?
| | Aged, 80 and over | 1 | 2023 | 7066 | 0.090 |
Why?
| | Carotid Arteries | 2 | 2024 | 196 | 0.090 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 766 | 0.090 |
Why?
| | Motor Neurons | 1 | 2013 | 233 | 0.090 |
Why?
| | Spinal Cord | 1 | 2013 | 355 | 0.090 |
Why?
| | Knee Joint | 1 | 2014 | 375 | 0.090 |
Why?
| | Case-Control Studies | 4 | 2019 | 3384 | 0.080 |
Why?
| | Sepsis | 1 | 2016 | 576 | 0.080 |
Why?
| | Follow-Up Studies | 1 | 2018 | 4896 | 0.080 |
Why?
| | Biological Availability | 2 | 2021 | 147 | 0.070 |
Why?
| | Heart Failure | 1 | 2019 | 2148 | 0.060 |
Why?
| | Photoplethysmography | 2 | 2016 | 18 | 0.060 |
Why?
| | Fingers | 2 | 2016 | 86 | 0.060 |
Why?
| | Infusions, Intra-Arterial | 2 | 2015 | 53 | 0.050 |
Why?
| | Respiratory Therapy | 1 | 2023 | 23 | 0.050 |
Why?
| | Elastic Modulus | 1 | 2024 | 123 | 0.050 |
Why?
| | Nitric Oxide Synthase | 2 | 2015 | 237 | 0.050 |
Why?
| | Time Factors | 3 | 2021 | 6550 | 0.050 |
Why?
| | Nitric Oxide Synthase Type III | 2 | 2016 | 203 | 0.050 |
Why?
| | Lower Extremity | 2 | 2019 | 407 | 0.050 |
Why?
| | Forearm | 1 | 2023 | 117 | 0.050 |
Why?
| | Hypercapnia | 1 | 2023 | 50 | 0.050 |
Why?
| | Muscles | 1 | 2023 | 320 | 0.050 |
Why?
| | Injections, Spinal | 1 | 2021 | 111 | 0.050 |
Why?
| | Carbon Dioxide | 1 | 2023 | 260 | 0.050 |
Why?
| | Nicotine | 1 | 2023 | 304 | 0.050 |
Why?
| | Blood Circulation | 1 | 2021 | 41 | 0.040 |
Why?
| | Neurons, Afferent | 1 | 2021 | 101 | 0.040 |
Why?
| | Analgesics, Opioid | 2 | 2021 | 925 | 0.040 |
Why?
| | Cerebrovascular Circulation | 1 | 2023 | 228 | 0.040 |
Why?
| | Social Determinants of Health | 1 | 2024 | 226 | 0.040 |
Why?
| | Random Allocation | 1 | 2021 | 347 | 0.040 |
Why?
| | Mouth | 1 | 2021 | 84 | 0.040 |
Why?
| | Interleukin-6 | 1 | 2024 | 724 | 0.040 |
Why?
| | Enzyme Inhibitors | 2 | 2015 | 827 | 0.040 |
Why?
| | Infusions, Intralesional | 1 | 2019 | 1 | 0.040 |
Why?
| | Diet, High-Fat | 1 | 2021 | 239 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2024 | 615 | 0.040 |
Why?
| | Adrenergic Antagonists | 1 | 2019 | 8 | 0.040 |
Why?
| | Retrospective Studies | 1 | 2016 | 14553 | 0.040 |
Why?
| | Risk Assessment | 2 | 2019 | 3269 | 0.040 |
Why?
| | Blood Pressure Determination | 1 | 2019 | 148 | 0.040 |
Why?
| | Risk Factors | 2 | 2024 | 9801 | 0.040 |
Why?
| | Immunity, Innate | 1 | 2024 | 804 | 0.040 |
Why?
| | Reference Values | 1 | 2019 | 796 | 0.040 |
Why?
| | Oxygen | 1 | 2022 | 916 | 0.040 |
Why?
| | Oxidative Phosphorylation | 1 | 2018 | 188 | 0.040 |
Why?
| | ROC Curve | 1 | 2019 | 504 | 0.030 |
Why?
| | Homeostasis | 1 | 2021 | 605 | 0.030 |
Why?
| | Energy Intake | 1 | 2020 | 462 | 0.030 |
Why?
| | Adipose Tissue | 1 | 2021 | 594 | 0.030 |
Why?
| | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2016 | 41 | 0.030 |
Why?
| | Electron Transport Complex IV | 1 | 2016 | 57 | 0.030 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2016 | 52 | 0.030 |
Why?
| | Program Development | 1 | 2018 | 355 | 0.030 |
Why?
| | Electron Transport Complex II | 1 | 2015 | 25 | 0.030 |
Why?
| | Electron Transport Complex I | 1 | 2015 | 39 | 0.030 |
Why?
| | Biopsy | 1 | 2018 | 1089 | 0.030 |
Why?
| | Pilot Projects | 1 | 2020 | 1597 | 0.030 |
Why?
| | Afferent Pathways | 1 | 2014 | 46 | 0.030 |
Why?
| | Evoked Potentials, Motor | 1 | 2014 | 40 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 1951 | 0.030 |
Why?
| | Electromagnetic Fields | 1 | 2013 | 23 | 0.030 |
Why?
| | Program Evaluation | 1 | 2018 | 878 | 0.030 |
Why?
| | Amino Acids, Branched-Chain | 1 | 2013 | 36 | 0.030 |
Why?
| | Pulmonary Gas Exchange | 1 | 2013 | 121 | 0.030 |
Why?
| | Microbiota | 1 | 2021 | 734 | 0.030 |
Why?
| | Endothelin A Receptor Antagonists | 1 | 2012 | 24 | 0.030 |
Why?
| | Physical Exertion | 1 | 2014 | 210 | 0.030 |
Why?
| | Exercise Therapy | 1 | 2017 | 413 | 0.030 |
Why?
| | Femoral Vein | 1 | 2012 | 32 | 0.020 |
Why?
| | Receptor, Endothelin A | 1 | 2012 | 63 | 0.020 |
Why?
| | Stress, Mechanical | 1 | 2014 | 467 | 0.020 |
Why?
| | Tryptophan | 1 | 2013 | 177 | 0.020 |
Why?
| | Catheterization, Peripheral | 1 | 2012 | 105 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2739 | 0.020 |
Why?
| | Vascular Resistance | 1 | 2012 | 371 | 0.020 |
Why?
| | Colorado | 1 | 2021 | 4410 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2012 | 541 | 0.020 |
Why?
| | Ultrasonography | 1 | 2015 | 713 | 0.020 |
Why?
| | Lactic Acid | 1 | 2012 | 304 | 0.020 |
Why?
| | Lipids | 1 | 2014 | 628 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 3773 | 0.020 |
Why?
| | Cohort Studies | 1 | 2019 | 5444 | 0.020 |
Why?
| | Transcription Factors | 1 | 2016 | 1645 | 0.020 |
Why?
| | Obesity | 1 | 2021 | 2885 | 0.020 |
Why?
| | Prospective Studies | 1 | 2019 | 7158 | 0.020 |
Why?
| | Phenotype | 1 | 2014 | 3062 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 5085 | 0.010 |
Why?
|
|
Rossman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|